This channel includes news on cardiovascular care delivery, including how patients are diagnosed and treated, cardiac care guidelines, policies or legislation impacting patient care, device recalls that may impact patient care, and cardiology practice management.
The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.
For artificial intelligence to truly transform care, the healthcare industry must address certain challenges. Jens Eldrup-Jorgensen, MD, a veteran vascular surgeon and member of the Society for Vascular Surgery, explains in a guest editorial.
The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks.
U.S. News and World Report recently released its rankings of the Best Children’s Hospitals by Specialty in 2023, designating 10 of them to their Honor Roll for excelling in multiple specialties.
Did your facility make the cut? For its 2023-2024 list, U.S. News and World Report evaluated data from 119 hospitals and surveyed thousands of pediatric specialists.
Patient names, addresses, social security numbers and even medical histories were exposed as a result of the attack, which went unnoticed for more than two months.
If healthcare AI is to flourish outside of academic research settings and industry R&D departments, it will need to win over its most difficult-to-impress audience: healthcare workers in hospitals.
The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.
The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks.
Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.
